RVNC
- Revance Therapeutics, Inc.
()
Overview
Company Summary
Revance Therapeutics, Inc. (RVNC) is a biotechnology company that focuses on developing and commercializing innovative products for aesthetic and therapeutic medical fields. Their primary area of expertise lies in the development of neuromodulators, which are substances used to regulate nerve activity.
Revance Therapeutics is widely recognized for its proprietary platform technology called the RHA� Collection, which stands for Resilient Hyaluronic Acid. This technology enables the company to create and formulate long-lasting injectable products for aesthetic purposes, such as reducing the appearance of facial wrinkles and folds.
One of their flagship products is DaxibotulinumtoxinA, commonly referred to as DAXI. DAXI is an investigational neuromodulator that has demonstrated prolonged effects and is being developed as a potential alternative to the current market-leading products in the field of facial aesthetics.
In addition to their aesthetic product pipeline, Revance Therapeutics is also working on therapeutic applications of their technology. They are conducting research and development to explore the use of their neuromodulator products in various therapeutic areas, including cervical dystonia, plantar fasciitis, and migraine prevention.
Overall, Revance Therapeutics focuses on utilizing its innovative technology to develop and commercialize advanced neuromodulator products for both aesthetic and therapeutic purposes, aiming to provide patients with more effective and longer-lasting treatment options in the field of medical aesthetics and neurology.